BiotechTube

Linaclotide

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome With Constipation

Conditions

Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation

Trial Timeline

Nov 1, 2015 → Feb 5, 2018

NCT ID
NCT02590432

About Linaclotide

Linaclotide is a approved stage product being developed by Ironwood Pharmaceuticals for Irritable Bowel Syndrome With Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT02590432. Target conditions include Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation.

What happened to similar drugs?

6 of 20 similar drugs in Irritable Bowel Syndrome With Constipation were approved

Approved (6) Terminated (1) Active (14)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved
🔄YM060 + PlaceboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02590432ApprovedCompleted
NCT00765999Phase 3Completed
NCT00730171Phase 3Completed

Competing Products

20 competing products in Irritable Bowel Syndrome With Constipation

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29